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Abstract 
 Proton pump inhibitors (PPIs) are the most commonly prescribed class of medication for 
gastric acid-related conditions. They are generally well-tolerated, have a seemingly high safety 
profile, and have superior acid-suppressing capabilities compared to other agents, but new 
evidence suggests the long-term use of PPI therapy may not come without consequence (Strand, 
Kim, & Peura, 2017). Recently, research discovered a potential association between PPI use and 
a variety of medical complications such as enteric infection, pneumonia, malabsorption of 
vitamins and minerals, renal disease, and bone fracture. This review investigates the association 
between PPI use and an individual’s risk for bone fracture and includes a case presentation, 
which illustrates a situation in which PPI therapy is considered for the treatment of 
gastroesophageal reflux disease (GERD). Furthermore, an analysis of recently-published 
academic literature regarding PPI use and bone health is presented.  
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Background 
Proton pump inhibitors were first introduced by a Swedish pharmaceutical company in 
1979 and are now one of the most commonly prescribed classes of medications worldwide 
(Connelly, 2016). They are well-tolerated and highly effective – qualities which have made them 
the hallmark of treatment for gastric acid-related disorders (Strand et al., 2017). Proton pump 
inhibitor therapy is indicated for the treatment of numerous gastrointestinal conditions including 
dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), Barrett’s 
esophagus, eosinophilic esophagitis, stress gastritis, and Zollinger-Ellison syndrome (ZES) 
(Strand et al., 2017). Proton pump inhibitors are also used to prevent nonsteroidal anti-
inflammatory drug (NSAID) associated ulcer formation and play a role in Helicobacter pylori 
infection eradication (Strand et al., 2017). Currently, six PPIs are approved for use in the United 
States of America – omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and 
rabeprazole (Strand et al., 2017). 
Proton pump inhibitors were initially thought to have a high safety profile, but recent 
literature suggests otherwise. Several research studies found PPI use may be associated with 
several medical complications including an increased risk of bone fracture; however, the results 
among studies are controversial and a causal relationship between PPI use and bone fracture has 
yet to be identified.  
This review was created to further examine PPI use and its effect on bone health. The 
next section describes a case report of a 52-year-old woman with a cough. The patient’s 
assessment and examination findings correlated with two possible diagnoses, one of which may 
have required PPI therapy. Following the case report, 10 research articles pertaining to PPIs and 
bone health were analyzed in a literature review.  
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Case Report 
A 52-year-old Caucasian female presented to the clinic with complaints of a dry, non-
productive cough that started three months prior. She described the cough as bothersome and 
stated, “I feel like I have a constant tickle in my throat.” It was present upon wakening, persisted 
throughout the day, and was more prominent at night or after she consumed a large meal. She 
tried over-the-counter (OTC) cough suppressants and cough drops, but they did not provide 
much relief. To the best of her knowledge, she had not been around anyone that was ill. She was 
concerned she contracted a form of influenza, but a system review, history assessment, and 
physical examination revealed findings inconsistent with an influenza infection. 
 She did not feel unwell and denied fever, chills, headache, fatigue, weakness, and 
tiredness. She had not experienced changes in her vision, hearing, or taste and had no complaints 
of ear pain, tinnitus, nasal congestion, nasal drainage, sinus pressure, sinus tenderness, or sore 
throat. She denied chest pain, nor did she feel short of breath. Occasionally, she would get 
heartburn, but OTC antacids effectively relieved the discomfort. She denied abdominal pain, 
nausea, vomiting, diarrhea, constipation, hematochezia, and changes in urination including 
urgency, frequency, dysuria, and hematuria. She had no complaints of myalgias, arthralgias, or 
changes in her skin and denied feelings of anxiety or depression.  
The patient’s personal and familial medical history was relatively insignificant. She was 
an only child and her mother and father were, at the time, alive and healthy. Her past surgical 
history was unremarkable and her only medical problem included hypertension, for which she 
was prescribed lisinopril six months earlier. She never used tobacco or illicit drugs; she would 
drink wine on occasion. Her dietary habits were concerning – she was a heavy coffee drinker (3-
5 cups daily) and she often consumed large, “fulfilling” meals. She was married, worked at a 
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local university, and had two children who lived at home. There were no pets in the household. 
She received all her childhood vaccinations and had been vaccinated for the current influenza 
season.  
The patient’s physical examination was unremarkable. Her vital signs were normal. She 
was alert, oriented, and did not appear in distress. No abnormalities were noted upon assessment 
of her head, eyes, ears, nose, and oral cavity. Inspection and assessment of her neck found no 
adenopathy, thyromegaly, or tracheal deviation. Her lung sounds were clear in all fields upon 
auscultation, although, a dry cough was noted. Active bowel sounds were present in all four 
abdominal quadrants, and her abdomen was soft and non-tender to palpation. A genitourinary 
assessment was deferred. The patient’s skin was pink, warm, dry, and intact. Her behavior was 
appropriate, and she did not appear anxious.  
The patient’s assessment and examination findings correlated with four differential 
diagnoses. The first differential diagnosis was GERD. The patient’s cough was more prominent 
at night and after she ate a large meal. Additionally, she was an avid coffee drinker and would 
occasionally experience heartburn. The second differential diagnosis was a lisinopril-induced 
cough. Lisinopril is an angiotensin-converting-enzyme (ACE) inhibitor, a class of medication 
known to cause a dry, hacking, bothersome cough. The onset of a cough caused by ACE 
inhibitors ranges from hours to months; she began treatment with lisinopril six months 
beforehand. The third and fourth differential diagnoses included post-nasal drip and upper 
respiratory infection.  
The medical profile of each diagnosis was carefully analyzed. The patient’s chief 
complaint, related findings, and lifestyle habits correlated most GERD, but a lisinopril-induced 
cough could not be confidently ruled out. It was decided to involve the patient in the plan of care. 
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Each potential diagnosis was discussed in detail and the patient’s questions and concerns were 
addressed. She was given two options – she could continue taking the lisinopril and begin short-
term PPI therapy or she could forgo PPI therapy and switch her antihypertensive medication. The 
patient chose to change the lisinopril to hydrochlorothiazide. She was supposed to schedule an 
appointment two weeks later for symptom re-evaluation. If her symptoms remained, short-term 
PPI therapy would then be recommended. 
Literature Review 
 The above case report illustrates how easy it could be to over-prescribe PPIs or to 
prescribe them for inappropriate conditions. Many patients use PPIs to control symptoms of 
chronic conditions, meaning they are often used for extended periods of time. Proton pump 
inhibitor use has increased dramatically in recent years, especially among geriatric populations, 
but they are also being prescribed to children and young adults for non-specific symptoms 
(Freedberg et al., 2015). Proton pump inhibitors are available over-the-counter or by 
prescription; therefore, it is impossible to estimate how many individuals use these agents, but 
pharmacological data approximates 113 million prescriptions are filled each year worldwide 
(University of California Berkeley School of Public Health, 2017). This widespread use of PPIs 
has generated concern about their long-term safety profile, including their effect on the skeletal 
system. If PPI use is found to negatively impact skeletal health, it will be important for clinicians 
to become more cognizant of their prescribing habits. To further investigate the relationship 
between PPIs and their effect on bone health, a literature review was performed.  
Literature Search 
A search for literary material was conducted using two research databases, the 
Cumulative Index to Nursing and Allied Health (CINAHL) and PubMed. Between the two 
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databases, 32 articles were chosen for more in-depth evaluation, and 10 were deemed useful for 
this review. Due to differences among database filters, the search limitations were not identical, 
but similar. With CINAHL, each search was limited to text in the English language that was 
published in an academic journal between 2013 and 2018. With PubMed, article types were 
limited to case reports, clinical studies, clinical trials, comparative studies, controlled clinical 
trials, practice guidelines, meta-analyses, observational studies, randomized controlled trials, and 
systematic reviews. The results were further limited to those that involved only human subjects, 
were published between 2013 and 2018, and were in the English language. Five search phrases 
were used with each database: long-term use of proton pump inhibitors, proton pump inhibitors 
and osteoporosis, side effects of proton pump inhibitors, proton pump inhibitors and calcium 
absorption, and proton pump inhibitors and fracture. The first search phrase, long-term use of 
proton pump inhibitors, yielded 38 results within CINAHL. Due to the high yield, the results 
were sorted by “most relevant,” and the first 20 texts listed were evaluated; four were chosen for 
further review. The remaining four phrases yielded 13, 15, 8, and 15 results, respectively, all of 
which were screened for relevancy. Of these, 11 were further reviewed. With PubMed, each 
search phrase, other than proton pump inhibitors and calcium absorption (18 results), yielded a 
tremendously high number of results. The phrases long-term use of proton pump inhibitors, 
proton pump inhibitors and osteoporosis, and proton pump inhibitors and fracture yielded 335, 
43, and 80 results, respectively. The phrase side effects of proton pump inhibitors yielded 1,343 
results, many of which were duplicates of prior searches. All results were sorted by “best match,” 
and the first 20 texts listed were screened for relevancy. Seventeen articles were further 
examined. 
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Many of the 32 articles contained information and statistics on both PPIs and bone health, 
but over half-were deemed irrelevant or were reviews of primary studies already chosen for use. 
Four articles concentrated on PPI use and its effect on gastrointestinal absorption of vitamins and 
minerals; the information provided was determined to be insignificant to the overall objective of 
this review, so they were discarded. One article from CINAHL utilized rats as research subjects 
and was excluded. The remaining omitted articles contained generalized information about PPIs, 
only referenced research studies to emphasize a point, or focused on PPI use in conjunction with 
other medications and medical conditions. 
 Ten articles were selected and consisted of 5 literature reviews, 2 cohort studies, 2 case-
control studies, and one cross-sectional study. All the articles investigated the effect of PPI use 
on the skeletal system – four specifically focused on PPI use and an increased risk for bone 
fracture, while the other 6 examined the association between PPI use and changes in bone 
mineral density (BMD), the development of osteoporosis, and the incidence of osteoporotic 
fracture.  
Proton Pump Inhibitors and Bone Fracture 
 Bone fractures occur in individuals of all ages and are either traumatic or pathologic in 
nature. Pathological fractures occur when an underlying cause weakens the bone structure, 
making it more susceptible to break. Recently, it has been suggested that PPI use may negatively 
affect bone metabolism and increase an individual’s risk of fracture. Abramowitz et al. (2016) 
conducted a systematic review and determined PPI users were more likely to experience an “any-
site”, spinal, or hip fracture compared to non-PPI users. Spinal fractures among PPI users had the 
highest odds ratio (OR) of 1.50 followed by hip fractures, which had an OR of 1.30; the OR 
range for “any-site” fractures varied from 1.44-2.65, but the information was collected from low 
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quality research (Abramowitz et al., 2016). Comparably, Zhou, Huang, Li, Sun, and Liu (2016) 
found a moderate increase in spine (95% CI 1.38-1.82) and hip (95% CI 1.16-1.36) fracture risk 
among PPI users. The authors considered the presence of heterogeneity among the studies that 
investigated hip fracture risk and performed a stratified analysis that limited the review to cohort 
studies – a moderate increase in fracture risk was still found (95% CI 1.06-1.45) (Zhou et al., 
2016).  
 Most of the literature on PPI use and increased risk of bone fracture focus on menopausal 
women or the elderly. To further strengthen the association between PPI use and increased risk 
of bone fracture, Adams et al. (2014) and Freedberg et al. (2015) conducted studies using men, 
children, and young adults as participants. The study by Adams et al. (2014) examined men aged 
45 years or older; the case subjects had sustained a hip fracture during the study period, whereas 
the control subjects had not. Freedberg et al.’s (2015) study included male and female 
individuals between 4 and 29 years age. Like Adams et al. (2014), Freedberg et al.’s (2015) case 
selection included individuals who sustained any fracture; those in the control group had no 
history or diagnosis of fracture. The exposure of interest in both studies was PPI use and both 
studies further evaluated whether dosage and duration of PPI therapy affected the results. Both 
studies found an association between PPI use and an increased risk of bone fracture; however, 
Freedberg et al. (2015) only found an association among young adults (18-29 years old), not 
among children (4-18 years old). Adams et al.’s (2014) study found men who took omeprazole 
(for an average of 150 days) and were compliant with treatment had an increased risk of hip 
fracture (OR 1.31) versus non-PPI users. Freedberg et al. (2015) discovered young adults who 
had been exposed to at least 180 cumulative doses of PPI therapy had a significantly increased 
risk of hand and foot fractures (OR 1.39).  
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Proton Pump Inhibitors and Changes in Bone Mineral Density 
Bone mineral density measurements reflect an individual’s overall bone health. Low 
BMD values are associated with osteoporosis and increased fracture risk and are often a result of 
aging, genetics, disease, or medication use. Osteoporosis has become a major medical concern – 
it is estimated that 1 in 3 women and 1 in 5 men over 50 years old will experience an 
osteoporotic fracture in their lifetime (Byreddy, Bouchonville, & Lewiecki, 2015).  
Proton pump inhibitors have been implicated as increasing a person’s bone fracture risk. 
Recent research has focused on BMD changes among PPI users, but the findings are 
inconsistent. Arj et al. (2016) and Solomon et al. (2015) evaluated femur and lumbar T-scores in 
PPI users and non-PPI users; a T-score < -2.5 was indicative of osteoporosis and a T-score 
between -2.5 and -1 indicated osteopenia. Arj et al. (2016) conducted a cross-sectional study that 
included males and females between 20 and 45 years of age and found a significant decrease of 
mean femoral and lumbar T-scores (-0.44 ± 1.11, -0.94 ± 0.92) in subjects who had been on PPI 
therapy for at least two years compared to non-PPI users (0.19 ± 0.95, -0.53 ± 1.24). On the 
contrary, Solomon et al.’s (2015) findings failed to correlate PPI use with decreased BMD –  the 
mean femoral and lumbar T-scores of PPI users (0.83 ± 0.13, 1.07 ± 0.16) were comparable to 
those of non-users (0.78 ± 0.12, 1.16 ± 0.24). 
Fraser et al. (2013) decided to take a unique route by prospectively examining the 
association of PPI use and incident of fragility fracture while using BMD as a controlled 
confounding variable. The results indicated PPI use was associated with incident fragility 
fracture, even after adjusting for baseline femoral T-scores. Byreddy et al. (2015) and Andersen, 
Johansen, and Abrahamsen (2016) searched the literature for evidence to substantiate the 
association of PPI use and the development of osteoporosis and increased risk of bone fracture. 
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The authors found numerous studies which further support the association of PPI use and 
changes in bone health, but they also identified widespread diversity among the research; 
therefore, they propose further inquiry on the topic is needed. 
Special Considerations 
The most common finding among the studies was that fracture risk was dependent on PPI 
formulation, dosage, and duration of therapy – longer, more intense PPI therapy as well as 
certain PPI formularies (omeprazole and esomeprazole) were significantly associated with an 
increased risk of bone fracture and changes in BMD. Additionally, even though an association 
has been found between PPI use and increased risk of bone fracture, the mechanism of action 
remains unknown. Mulcahy (2015) set out to find a causal relationship between PPI use and 
development of osteoporosis and increased risk of bone fracture. She reviewed eight studies that 
found fracture risk is increased in women who use PPIs, but none were able to explain why, 
leaving her to conclude that although an association exists between PPI and fracture risk, the 
causation has yet to be discovered (Mulcahy, 2015).  
There is no doubt that more information and further investigation is needed on this topic. 
It will be interesting to watch the body of evidence grow; however, some researchers have 
voiced concern over the ethical aspects and feasibility of randomized control trials. Until more 
data can be gathered, “we must rely on observational studies” (Fraser et al., 2013, p. 1164).  
Learning Points 
Current evidence regarding long-term PPI use and increased risk for bone fracture is 
inconsistent and controversial, but if an association between the two is proven to exist, treatment 
guidelines and recommendations for gastric acid-related disorders will need to be revised. It is 
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important for clinicians to carefully evaluate individuals before prescribing PPI therapy. 
Furthermore, it is apparent that additional research on the long-term effects of PPI use is needed. 
In conclusion, this report adds to the growing body of evidence that PPI use may be 
associated with an increased risk of bone fracture and offers the following clinical considerations 
for health care providers:  
• Proton pump inhibitors were once thought to be relatively safe, but new evidence 
suggests they may be associated with several medical complications including an 
increased risk for bone fracture.  
• Proton pump inhibitors are over-prescribed or prescribed inappropriately, making 
them one of the world’s most commonly prescribed class of medications. Careful 
evaluation of individuals with gastric acid-related disorders is essential before 
initiating PPI therapy.  
• If PPI therapy must be initiated, clinicians should consider the patient’s age and 
comorbid burden. The lowest recommended dose for the shortest duration of time 
should be prescribed and alternative treatments should be used in high-risk 
individuals.  
• Further research regarding PPI therapy and bone fracture is needed. This may be 
difficult because prospective, randomized, controlled studies may be considered 
unethical or unfeasible; however, research into the underlying mechanism by 
which PPI use increases the risk for fracture may be beneficial. 
  
PROTON PUMP INHIBITORS AND BONE FRACTURE RISK 14 
 
References 
Abramowitz, J., Thakkar, P., Isa, A., Truong, A., Park, C., & Rosenfeld, R. M. (2016). Adverse 
event reporting for proton pump inhibitor therapy: An overview of systematic 
reviews. Otolaryngology - Head & Neck Surgery, 155(4), 547-554. Retrieved from 
http://ezproxylr.med.und.edu:2056/10.1177/0194599816648298 
Adams, A. L., Black, M. H., Zhang, J. L., Shi, J. M., & Jacobsen, S. J. (2014). Proton-pump 
inhibitor use and hip fractures in men: A population-based case-control study. Annals of 
Epidemiology, 24(4), 286-290. Retrieved from 
https://doi.org/10.1016/j.annepidem.2014.01.004 
Andersen, B. N., Johansen, P. B., & Abrahamsen, B. (2016). Proton pump inhibitors and 
osteoporosis. Current Opinion in Rheumatology, 28(4), 420-425. Retrieved from 
http://ezproxylr.med.und.edu:2056/10.1097/BOR.0000000000000291 
Arj, A., Razavi Zade, M., Yavari, M., Akbari, H., Zamani, B., & Asemi, Z. (2016). Proton pump 
inhibitors use and change in bone mineral density. International Journal of Rheumatic 
Diseases, 19(9), 864-868. doi:10.1111/1756-185X.12866 
Byreddy, D. V., Bouchonville, M. F., II, & Lewiecki, E. M. (2015). Drug-induced osteoporosis: 
From Fuller Albright to aromatase inhibitors. Climacteric, 18(2), 39-46. 
doi:10.3109/13697137.2015.1103615 
Connelly, D. (2016). The development and safety of proton pump inhibitors. The Pharmaceutical 
Journal, 296(7890), 348-349. doi:10.1211/PJ.2016.20201343 
Fraser, L. A., Leslie, W. D., Targownik, L. E., Papaioannou, A., Adachi, J. D., & CaMos 
Research Group. (2013). The effect of proton pump inhibitors on fracture risk: Report 
PROTON PUMP INHIBITORS AND BONE FRACTURE RISK 15 
 
from the Canadian Multicenter Osteoporosis Study. Osteoporosis International, 24(4), 
1161-1168. doi:10.1007/s00198-012-2112-9 
Freedberg, D. E., Haynes, K., Denburg, M. R., Zemel, B. S., Leonard, M. B., Abrams, J. A., & 
Yang, Y.-X. (2015). Use of proton pump inhibitors is associated with fractures in young 
adults: A population-based study. Osteoporosis International, 26(10), 2501-2507. 
doi:10.1007/s00198-015-3168-0 
Mulcahy, E. A. (2015). The state of the science of proton pump inhibitors causing osteoporotic 
changes in postmenopausal women. Gastroenterology Nursing, 38(2), 129-133. Retrieved 
from http://ezproxylr.med.und.edu:2056/10.1097/SGA.0000000000000102 
Solomon, D. H., Diem, S. J., Ruppert, K., Lian, Y. J., Liu, C. C., Wohlfart, A., . . . Finkelstein, J. 
S. (2015). Bone mineral density changes among women initiating proton pump inhibitors 
or H2 receptor antagonists: A SWAN cohort study. Journal of Bone and Mineral 
Research, 30(2), 232-239. doi:10.1002/jbmr.2344 
Strand, D. S., Kim, D., & Peura, D. A. (2017). 25 years of proton pump inhibitors: A 
comprehensive review. Gut and Liver, 11(1), 27-37. doi:10.5009/gnl15502 
University of California Berkeley School of Public Health (2017). Proton pump inhibitors: How 
safe are they? Retrieved from 
https://www.healthandwellnessalerts.berkeley.edu/alerts/digestive_health/How-Safe-
AreProton-Pump-Inhibitors_7793-1.html 
Zhou, B., Huang, Y., Li, H., Sun, W., & Liu, J. (2016). Proton-pump inhibitors and risk of 
fractures: An update meta-analysis. Osteoporosis International, 27(1), 339-347. 
doi:10.1007/s00198-015-3365-x 
 
